See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $223B | 3.5x | 8.2x | |
| $167B | 2.6x | 6.9x | |
| $128B | 2.7x | 9.1x | |
| $84.7B | 2.1x | 6.0x | |
| $81.6B | 5.3x | 15.9x | |
| $28.6B | 4.2x | 16.2x | |
| $11.2B | 25.7x | 71.9x | |
| $8.4B | 2.1x | 15.5x | |
| $5.2B | 11.8x | 38.8x | |
| $5.1B | 1.8x | -4.0x | |
| $4.6B | 5.5x | 20.7x | |
| $3.9B | 1.3x | -1.0x | |
| $3.8B | 6.2x | 14.5x | |
| $2.7B | 7.4x | 41.9x | |
| $2.7B | 66.0x | n/a | |
| $2.5B | 5.9x | 19.5x | |
| $2.4B | n/a | n/a | |
| $2.3B | n/a | n/a | |
| $2.0B | 4.7x | 14.3x | |
| $1.9B | 14.8x | -20.5x | |
| $1.5B | 6.0x | -25.0x | |
| $1.3B | 1.6x | 5.5x | |
| $1.3B | n/a | n/a | |
| $1.1B | n/a | n/a | |
| $1.1B | 5.7x | 7.7x | |
| $1.0B | n/a | n/a | |
| $936M | 3.2x | 21.8x | |
| $917M | n/a | n/a | |
| $890M | 6.1x | 12.7x | |
| $882M | n/a | n/a | |
| $688M | 3.8x | n/a | |
| $688M | 2.9x | 10.1x | |
| $683M | n/a | n/a | |
| $663M | 15.2x | n/a | |
| $613M | n/a | n/a | |
| $591M | n/a | n/a | |
| $535M | 2.8x | 39.8x | |
| $490M | n/a | n/a | |
| $484M | n/a | n/a | |
| $405M | 57.7x | -1.4x | |
| $403M | n/a | n/a | |
| $396M | 65.4x | -2.0x | |
| $373M | 6.8x | -20.4x | |
| $352M | 4.8x | -13.7x | |
| $350M | n/a | n/a | |
| $341M | 90.6x | -18.8x | |
| $285M | 1.7x | 8.1x | |
| $250M | 0.4x | -2.0x | |
| $241M | 1.1x | -2.1x | |
| $234M | n/a | n/a | |
| $230M | n/a | n/a | |
| $212M | n/a | n/a | |
| $209M | n/a | n/a | |
| $176M | 60.6x | n/a | |
| $157M | 2.0x | -1.4x | |
| $155M | 0.3x | 1.1x | |
| $152M | n/a | n/a | |
| $149M | 14852.5x | n/a | |
| $146M | n/a | -4.1x | |
| $140M | n/a | n/a | |
| $124M | n/a | n/a | |
| $118M | 17.0x | -7.7x | |
| $114M | 180.6x | -1.9x | |
| $113M | 5842.5x | -0.4x | |
| $111M | n/a | n/a | |
| $108M | n/a | n/a | |
| $106M | 33.4x | -0.4x | |
| $101M | 64.5x | -1.2x | |
| $101M | n/a | n/a | |
| $97.5M | 0.9x | n/a | |
| $93.5M | 1.2x | 2.4x | |
| $88.2M | n/a | n/a | |
| $77.8M | 2.7x | n/a | |
| $75.7M | n/a | n/a | |
| $73.7M | 4.1x | -2.9x | |
| $71.7M | n/a | n/a | |
| $66.0M | n/a | n/a | |
| $63.5M | 11096.8x | -2.6x | |
| $48.1M | 10.8x | n/a | |
| $47.0M | 2.1x | n/a | |
| $41.5M | n/a | n/a | |
| $36.8M | n/a | n/a | |
| $33.8M | 4.2x | n/a | |
| $33.7M | 0.3x | -0.9x | |
| $33.3M | n/a | n/a | |
| $28.4M | 2415.0x | n/a | |
| $26.9M | n/a | -0.7x | |
| $26.8M | n/a | -1.2x | |
| $26.2M | n/a | n/a | |
| $19.3M | 20.1x | n/a | |
| $13.2M | 14.4x | n/a | |
| $12.2M | 0.5x | n/a | |
| $9.6M | n/a | n/a | |
| $9.3M | 1.8x | n/a | |
| $8.5M | 1.2x | -0.6x | |
| $5.4M | 64.5x | -0.2x | |
| -$1.7M | n/a | 0.0x | |
| -$1.7M | n/a | n/a | |
| -$2.2M | -0.0x | 0.0x | |
| -$3.0M | -0.3x | n/a | |
| -$4.7M | -4.4x | n/a | |
| -$6.8M | -0.3x | n/a | |
| -$7.1M | -1.3x | 0.6x | |
| -$9.0M | -0.9x | 0.7x | |
| -$9.7M | -1.5x | n/a | |
| -$10.4M | -0.6x | 0.2x | |
| -$20.2M | -0.1x | 0.3x | |
| -$23.2M | -26.2x | n/a | |
| -$24.1M | -5.9x | 0.3x | |
| -$29.6M | -0.9x | n/a | |
| -$30.4M | -1.0x | 0.9x | |
| -$33.6M | n/a | n/a | |
| -$37.7M | -0.4x | 0.3x | |
| -$42.1M | -40.6x | n/a | |
| -$45.5M | -5.5x | 1.0x | |
| -$48.6M | -0.4x | -2.1x | |
| -$49.1M | -0.8x | 0.1x | |
| -$52.2M | -0.2x | 0.2x | |
| -$54.5M | n/a | n/a | |
| -$62.4M | n/a | n/a | |
| -$63.2M | n/a | n/a | |
| -$66.9M | -18.7x | 0.4x | |
| -$70.3M | -6.6x | n/a | |
| -$72.3M | -6.7x | 0.4x | |
| -$73.3M | -34.5x | 0.8x | |
| -$75.3M | n/a | 0.6x | |
| -$82.8M | -0.7x | n/a | |
| -$85.9M | -51.7x | 0.6x | |
| -$91.7M | n/a | 0.9x | |
| -$115M | n/a | n/a | |
| -$115M | n/a | n/a | |
| -$119M | -52.0x | 1.0x | |
| -$123M | -30.7x | 1.0x | |
| -$123M | -684.4x | n/a | |
| -$141M | -1.0x | n/a | |
| -$173M | -9.8x | 0.8x | |
| -$182M | -4174.8x | 0.6x | |
| -$189M | n/a | 1.2x | |
| -$274M | -10.1x | 1.7x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies